| The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects. (NCT06994286) | Tanabe Pharma Corporation | 2025-06-24 |
| Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers (NCT06482346) | Tanabe Pharma Corporation | 2024-08-09 |
| A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL (NCT05658562) | Tanabe Pharma Corporation | 2023-01-30 |
| A Study of MT-0551 in Patients With Systemic Sclerosis (NCT05198557) | Tanabe Pharma Corporation | 2022-07-20 |
| A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) (NCT05240612) | Tanabe Pharma Corporation | 2022-05-02 |
| Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy (NCT05123196) | Tanabe Pharma Corporation | 2021-11-16 |
| Effects of Iron Supplements on the Pharmacokinetics of MT-6548 (NCT03645863) | Tanabe Pharma Corporation | 2018-08-27 |
| A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (NCT03570957) | Tanabe Pharma Corporation | 2018-07-17 |
| Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants (NCT03507738) | Tanabe Pharma Corporation | 2018-07-03 |
| Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (NCT03461146) | Tanabe Pharma Corporation | 2018-03-05 |
| Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy (NCT03436693) | Tanabe Pharma Corporation | 2018-02-15 |
| Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (NCT03439137) | Tanabe Pharma Corporation | 2018-02-14 |
| Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (NCT03402386) | Tanabe Pharma Corporation | 2018-01-03 |
| Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (NCT03329196) | Tanabe Pharma Corporation | 2017-10-30 |
| Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain (NCT03245008) | Tanabe Pharma Corporation | 2017-09-08 |